Vanda Pharmaceuticals
VNDA
4,05 €
Share price
-0.43%
Change (1 day)
-26.97%
Change (1 year)
Categories
Vanda Pharmaceuticals (VNDA) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : €0.10 Billion
According to Vanda Pharmaceuticals's latest financial reports the company's total liabilities are €0.10 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Vanda Pharmaceuticals - Total liabilities on balance sheet (from 2005 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | €0.11 B | 20.73% |
| 2023-12-31 | €93.65 M | -6.16% |
| 2022-12-31 | €99.79 M | 27.18% |
| 2021-12-31 | €78.46 M | 20.36% |
| 2020-12-31 | €65.19 M | 0.32% |
| 2019-12-31 | €64.98 M | 31.11% |
| 2018-12-31 | €49.57 M | -19.67% |
| 2017-12-31 | €61.7 M | -17.89% |
| 2016-12-31 | €75.14 M | 2.68% |
| 2015-12-31 | €73.18 M | 717.59% |
| 2014-12-31 | €8.95 M | -87.54% |
| 2013-12-31 | €71.84 M | -24.3% |
| 2012-12-31 | €94.9 M | -17.36% |
| 2011-12-31 | €0.11 B | -12.89% |
| 2010-12-31 | €0.13 B | -6.8% |
| 2009-12-31 | €0.14 B | 4953.51% |
| 2008-12-31 | €2.79 M | -68.87% |
| 2007-12-31 | €8.99 M | 24.87% |
| 2006-12-31 | €7.2 M | 67.69% |
| 2005-12-31 | €4.29 M | 222.13% |
| 2004-12-31 | €1.33 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | €53.22 B | 50,920.17% | 🇨🇭 Switzerland |
 Eli Lilly LLY | €63.65 B | 60,921.08% | 🇺🇸 USA |
 Johnson & Johnson JNJ | €100.03 B | 95,786.96% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | €64.90 B | 62,113.43% | 🇺🇸 USA |
 Pfizer PFE | €101.61 B | 97,304.56% | 🇺🇸 USA |
 Titan Pharmaceuticals
TTNP | €0.24 M | -99.77% | 🇺🇸 USA |
 Merck MRK | €57.75 B | 55,262.23% | 🇺🇸 USA |